J Gynecol Oncol.  2010 Jun;21(2):72-74. 10.3802/jgo.2010.21.2.72.

Evolving strategies for ovarian cancer: gynecologic oncology in ASCO's 46th annual meeting

• Kim TJ

• KMID: 2009573
• DOI: http://doi.org/10.3802/jgo.2010.21.2.72

Abstract

No abstract available.

Reference

1. Burger RA, Brady MF, Bookman MA, Walker JL, Homesley HD, Fowler J, et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J Clin Oncol. 2010. 28:7s. (suppl; abstr LBA1).

2. Lu KH, Skates S, Bevers TV, Newland W, Moore RG, Leeds L, et al. A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA). J Clin Oncol. 2010. 28:7s. (suppl; abstr 5003).

3. Teneriello MG, Gordon AN, Lim P, Janicek M. Phase III trial of induction gemcitabine (G) or paclitaxel (T) plus carboplatin (C) followed by elective T consolidation in advanced ovarian cancer (OC): Final safety and efficacy report. J Clin Oncol. 2010. 28:7s. (suppl; abstr LBA5008).

4. Karlan BY, Oza AM, Hansen VL, Richardson GE, Provencher DM, Ghatage P, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma. J Clin Oncol. 2010. 28:7s. (suppl; abstr 5000).

5. Pignata S, Scambia G, Savarese A, Sorio R, Breda E, Ferrandina G, et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): Final analysis of the MITO-2 randomized multicenter trial. J Clin Oncol. 2010. 28:7s. (suppl; abstr LBA5033).